Identifying and targeting new cancer drivers
Official title: Systematic Characterization and Targeting of Neomorphic Drivers in Cancer
Funded at Oregon Health & Science University · NIH-10931653 · Data updated 2026-11-12
This study is looking at specific changes in genes that can affect how certain cancers, like glioma, sarcoma, and endometrial cancer, grow and respond to treatment, with the hope of finding better ways to help patients fight these diseases.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $813,823 |
| NIH project number | 5U01CA281902-02 |
| Project ID | NIH-10931653 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioma, sarcoma, or endometrial cancers who have specific mutations or fusion genes.
✕Less likely to help
Patients with cancers not included in the study, or those without identifiable neomorphic drivers, may not benefit from this research.
What this research studies
This research focuses on understanding and targeting neomorphic drivers in various cancers, including glioma, sarcoma, and endometrial cancers. By utilizing advanced computational and experimental methods, the project aims to characterize mutations and fusion genes that alter tumor behavior and response to treatment. The goal is to identify biomarkers that can predict how these changes affect cancer progression and treatment outcomes, ultimately leading to more effective therapies for patients. The research will explore the functional consequences of these genetic alterations to improve cancer treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective cancer treatments by targeting specific genetic alterations in tumors.
How similar studies have gone: Other research has shown promise in targeting genetic alterations in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Mills, Gordon B. — Oregon Health & Science University
- Study coordinator: Mills, Gordon B.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how a protein affects nerve cell movement in Alzheimer's disease
This study is looking at how a protein called APP affects the growth and movement of nerve cells, which is important for understanding Alzheimer's disease, and it aims to find out how problems with this protein might lead to nerve cell damage.
-
Understanding how the bone marrow environment drives AML resistance
A large NIH-funded project at Oregon Health & Science University is studying how the body’s own cell surroundings help acute myeloid leukemia become resistant to treatment, with potential paths to better therapies for patients.
-
Improving Safety at Work with a Low-Resource mHealth Program in Malaysia (and beyond)
A low-cost mobile health program to improve safety culture in Malaysian workplaces, with plans to adapt the approach for U.S. workers in high-risk industries.
-
Oregon Healthy Workplace Initiative for Better Health
A multi-site effort aims to improve the health and safety of workers by coordinating research, tools, and interventions across workplaces.
-
Understanding how AML cells become resistant to therapy over time
This project looks at why acute myeloid leukemia stops responding to treatment and how to design better drug combinations to prevent relapse.
-
Mechanisms and Countermeasures for Ultra-Potent Synthetic Opioid Overdose
A small, focused NIH grant aims to understand why ultra-potent synthetic opioids cause severe overdose and to explore potential countermeasures to keep people safe.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.